Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data.
10.4093/dmj.2017.41.5.393
- Author:
Sejeong PARK
1
;
Sang Youl RHEE
;
Su Jin JEONG
;
Kiyoung KIM
;
Suk CHON
;
Seung Young YU
;
Jeong Taek WOO
Author Information
1. Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. jtwoomd@khmc.or.kr
- Publication Type:Original Article
- Keywords:
Diabetes complications;
Diabetes mellitus, type 2;
Diabetic retinopathy;
Macular edema
- MeSH:
Cohort Studies;
Common Data Elements;
Diabetes Complications;
Diabetes Mellitus, Type 2*;
Diabetic Retinopathy*;
Hemoglobin A, Glycosylated;
Humans;
Insulin, Long-Acting;
Insulin, Short-Acting;
Korea;
Macular Edema;
Prevalence;
Prospective Studies
- From:Diabetes & Metabolism Journal
2017;41(5):393-404
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This is part of a prospective study carried out as a national project to secure standardized public resources for type 2 diabetes mellitus (T2DM) patients in Korea. We compared various characteristics of long-standing T2DM patients with diabetic retinopathy (DR) and macular edema (ME). METHODS: From September 2014 to July 2015, T2DM patients with disease duration of at least 15 years were recruited at a single university hospital. Clinical data and samples were collected according to the common data elements and standards of procedure developed by the Korean Diabetes Association Research Council. Each participant was assessed by ophthalmologists for DR and ME. RESULTS: Among 220 registered patients, 183 completed the ophthalmologic assessment. DR was associated with longer disease duration (odds ratio [OR], 1.071; 95% confidence interval [CI], 1.001 to 1.147 for non-proliferative diabetic retinopathy [NPDR]) (OR, 1.142; 95% CI, 1.051 to 1.242 for proliferative diabetic retinopathy [PDR]) and the use of long-acting insulin (OR, 4.559; 95% CI, 1.672 to 12.427 for NPDR) (OR, 4.783; 95% CI, 1.581 to 14.474 for PDR), but a lower prevalence of a family history of cancer (OR, 0.310; 95% CI, 0.119 to 0.809 for NPDR) (OR, 0.206; 95% CI, 0.063 to 0.673 for PDR). ME was associated with higher glycosylated hemoglobin levels (OR, 1.380; 95% CI, 1.032 to 1.845) and the use of rapid-acting insulin (OR, 5.211; 95% CI, 1.445 to 18.794). CONCLUSION: Various clinical features were associated with DR and ME. Additional epidemiological and biorepository-based studies using this cohort are being conducted to deepen our understanding of diabetic complications in Korea.
